XRF Scientific Limited (XRF) AI Stock Analysis

• Market Cap: AU$303.14M
• Dividend Yield: 2.18%
• Average Volume (3M): 240.16K
• Price to Earnings (P/E): 28.6
• Beta (1Y): 0.74
• Revenue Growth: -1.09%
• EPS Growth: 14.88%
• Country: AU
• Employees: N/A
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 0.04
• Shares Outstanding: 142,992,370
• 10 Day Avg. Volume: 163,831
• 30 Day Avg. Volume: 240,164
• PEG Ratio: 1.67
• Price to Book (P/B): 4.29
• Price to Sales (P/S): 4.34
• P/FCF Ratio: 30.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$2.35
• Price Target Upside: 14.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: AU$2.00 ▼(-2.91% Downside)

XRF Scientific Limited's overall stock score reflects strong financial performance with efficient operations and a solid balance sheet. However, mixed technical indicators and moderate valuation suggest limited growth potential without new catalysts. The absence of earnings call insights and corporate events further limits the score.

Positive Factors

Strong Profitability

High profitability margins indicate efficient operations and the ability to generate significant profit from sales, supporting long-term financial stability.

Low Leverage

Low leverage enhances financial flexibility and reduces risk, allowing the company to invest in growth opportunities without significant debt burden.

Operational Efficiency

Efficient operations enable the company to maintain profitability even in challenging market conditions, supporting sustainable long-term growth.

Negative Factors

Decline in Revenue Growth

Negative revenue growth suggests challenges in maintaining sales momentum, which could impact future profitability and market position if not addressed.

Decline in Free Cash Flow

Decreasing free cash flow may limit the company's ability to invest in new projects or return capital to shareholders, affecting long-term growth prospects.

Decreased Return on Equity

A decrease in return on equity indicates potential inefficiencies in asset utilization, which could impact overall profitability and shareholder returns.

XRF Scientific Limited Business Overview & Revenue Model

Company Description

XRF Scientific Limited (XRF) is an Australian-based company that specializes in the development and manufacture of analytical instrumentation, particularly focusing on X-ray fluorescence (XRF) technology. Operating primarily in the sectors of mining, minerals, and materials analysis, XRF provides high-quality products and services designed for elemental analysis, including instruments for laboratory and on-site applications. The company also engages in the production of consumables and accessories that support its analytical instruments, catering to a diverse range of industries including geology, environmental testing, and quality control.

How the Company Makes Money

XRF Scientific generates revenue through several key streams. Primarily, the company earns money from the sale of its XRF instruments, which are used for precise elemental analysis in various industries. This includes both the initial sale of the equipment and ongoing support services, such as maintenance and calibration. Additionally, XRF generates income from consumables, such as sample preparation materials and spare parts, which are essential for the operation of its instruments. The company also benefits from strategic partnerships with industry players and distributors, enhancing its market reach and sales capabilities. Furthermore, XRF may engage in research and development contracts or consultancy services, providing expert knowledge and tailored solutions that contribute to its revenue.

XRF Scientific Limited Financial Statement Overview

Summary

XRF Scientific Limited exhibits strong profitability and a robust balance sheet, with low leverage and efficient operations. However, the recent decline in revenue growth and free cash flow indicates potential challenges in sustaining growth. The company should focus on revitalizing sales and enhancing cash flow management to maintain its financial health.

Income Statement

XRF Scientific Limited demonstrates strong profitability with a consistent gross profit margin above 40% and a net profit margin improving to 17.47% in the latest year. However, the revenue growth rate has turned negative at -1.05%, indicating potential challenges in maintaining sales momentum. Despite this, the company maintains healthy EBIT and EBITDA margins, showcasing operational efficiency.

Balance Sheet

The company maintains a solid balance sheet with a low debt-to-equity ratio of 0.073, indicating prudent leverage management. The equity ratio is strong, reflecting a stable financial structure. However, the return on equity has slightly decreased, suggesting a need for improved profitability or asset utilization.

Cash Flow

XRF Scientific Limited's cash flow performance is mixed, with a decline in free cash flow growth at -10.41%. The operating cash flow to net income ratio is above 1, indicating good cash generation relative to profits. However, the free cash flow to net income ratio is slightly below 1, suggesting room for improvement in cash flow management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	59.45M	59.45M	59.84M	55.17M	40.01M	31.29M
Gross Profit	28.79M	28.79M	26.27M	22.00M	16.46M	12.89M
EBITDA	15.63M	15.63M	15.32M	13.22M	9.44M	8.05M
Net Income	10.38M	10.38M	8.89M	7.69M	6.08M	5.13M
Balance Sheet
Total Assets	72.79M	72.79M	68.23M	65.55M	55.56M	48.37M
Cash, Cash Equivalents and Short-Term Investments	12.23M	12.23M	12.05M	10.40M	6.65M	5.26M
Total Debt	4.41M	4.41M	3.38M	4.31M	3.51M	1.44M
Total Liabilities	12.62M	12.62M	12.69M	15.97M	12.21M	9.27M
Stockholders Equity	60.17M	60.17M	54.89M	49.25M	43.48M	39.10M
Cash Flow
Free Cash Flow	8.39M	8.39M	6.45M	7.63M	2.63M	3.86M
Operating Cash Flow	10.14M	10.14M	8.09M	8.42M	3.15M	4.51M
Investing Cash Flow	-2.21M	-2.21M	-1.64M	-782.43K	-1.11M	-652.62K
Financing Cash Flow	-7.75M	-7.75M	-4.80M	-3.88M	-648.95K	-2.24M

XRF Scientific Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.06
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:XRF, the sentiment is Positive. The current price of 2.06 is above the 20-day moving average (MA) of 1.90, above the 50-day MA of 2.04, and above the 200-day MA of 1.89, indicating a bullish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 58.33 is Neutral, neither overbought nor oversold. The STOCH value of 35.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:XRF.

XRF Scientific Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XRF	67 Neutral	AU$303.14M	28.61	18.05%	2.18%	-1.09%	14.88%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
KAU	46 Neutral	AU$151.44M	-4.98	-43.66%	―	46.74%	-47.98%
DTR	36 Underperform	AU$899.56M	-55.32	-183.07%	―	―	70.81%
GG8	36 Underperform	AU$273.38M	―	-6.62%	―	―	72.45%
MTM	32 Underperform	AU$577.38M	-12.37	-150.61%	―	―	-186.15%

XRF Scientific Limited Corporate Events

XRF Scientific Limited Announces Director’s Share Acquisition

XRF Scientific Limited announced a change in the director’s interest, specifically involving Vance Stazzonelli. The change involved an acquisition of 5,912 ordinary shares through an on-market trade, increasing his total holdings in the company. This adjustment in shareholding reflects ongoing investment and confidence in the company’s future prospects.

XRF Scientific Limited Passes Key Resolutions at 2025 AGM

XRF Scientific Limited held its 2025 Annual General Meeting, where key resolutions were passed, including the approval of the remuneration report, the re-election of Director David Brown, and the issuance of performance rights to Mr. Vance Stazzonelli. These decisions are expected to strengthen the company’s governance and incentivize leadership, potentially enhancing its operational effectiveness and market competitiveness.

XRF Scientific Showcases Advanced Sample Preparation Technology

XRF Scientific Limited presented its advanced technology in sample preparation and chemical analysis at its AGM in October 2025. The company’s focus on a wide range of minerals and materials positions it strongly in the mining and manufacturing sectors, enhancing its offerings to commercial labs and research institutions.

XRF Scientific Reports Strong Q3 2025 Results with International Sales Boost

XRF Scientific Limited reported a positive performance for the September 2025 quarter, with a 16% increase in revenue and a 7% rise in profit before tax compared to the previous year. The company’s international sales were strong, particularly in Canada, Belgium, and Germany, and it saw significant growth in its Orbis crushers and precious metals products. The company anticipates continued growth in the December quarter, focusing on international sales, new product developments, and M&A opportunities.

XRF Scientific Limited Announces Director’s Interest Change

XRF Scientific Limited announced a change in the director’s interest, specifically involving David William Kiggins. The change was due to the acquisition of 1,933 ordinary shares under a dividend reinvestment plan, increasing his indirect holdings through Glengarry Estate Pty Ltd. This adjustment reflects the company’s ongoing commitment to aligning leadership interests with shareholder value, potentially impacting stakeholder confidence positively.

Director’s Share Acquisition Reflects Confidence in XRF Scientific

XRF Scientific Limited has announced a change in the director’s interest, with Frederick Sheppard Grimwade acquiring 11,822 ordinary shares through a dividend reinvestment plan, increasing his total holdings to 563,527 shares. This change reflects the director’s continued confidence in the company’s performance and strategic direction, potentially impacting investor perceptions and stakeholder confidence positively.

XRF Scientific Limited Announces New Securities Quotation

XRF Scientific Limited has announced the issuance of 661,397 fully paid ordinary securities to be quoted on the Australian Securities Exchange (ASX) as of September 26, 2025. This move is part of a dividend or distribution plan, potentially impacting the company’s market presence and offering stakeholders an opportunity to engage with its financial growth.

XRF Scientific Limited Announces 2025 AGM with Key Resolutions

XRF Scientific Limited has announced its Annual General Meeting (AGM) scheduled for October 20, 2025, at the Quest Hotel in Innaloo, WA. The meeting will address key resolutions, including the adoption of the Remuneration Report and the re-election of Mr. David Brown as a director. These resolutions are significant for the company’s governance and strategic direction, impacting shareholder engagement and the company’s leadership structure.

XRF Scientific Director Diversifies Portfolio with Share Sale

XRF Scientific Limited announced a change in director David Brown’s shareholding, with Brown selling 1,000,000 shares for financial diversification purposes. Despite this sale, Brown has no immediate plans for further sales, and the transaction was executed through an on-market trade. This move reflects Brown’s strategy to diversify his investments, as a significant portion of his holdings are in XRF shares. The announcement, approved by the company’s board, highlights the director’s confidence in the company’s future performance, as he retains a substantial stake.